Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| CSL Behring (formerly ZLB Behring)-Therapeutic Competitors Report | Mar 2011 | £220 | 100% |
| CSL Behring (formerly ZLB Behring)-Deals & Alliances Report | Mar 2011 | £380 | 99% |
| CSL Limited – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 40% |
| Research Report on Global and Chinese Blood Product Industry, 2009 | Mar 2009 | £1,010 | 33% |
| Hemophilia Global Clinical Trials Review H2, 2011 |
Nov 2011 | £630 | 32% |
| Hemophilia A Global Clinical Trials Review H2, 2011 |
Oct 2011 | £630 | 32% |
| Blood Banking & Blood Products | Oct 2008 | £2,500 | 31% |
| Research Report on Global and China's Blood Products Industry 2011-2012 |
Feb 2010 | £1,390 | 31% |
| Blood Banking and Blood Products | Sep 2010 | £2,845 | 31% |
| Critical Care Market to 2017 Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles |
Sep 2011 | £2,215 | 31% |
| Hemophilia - Pipeline Review H2 2011 |
Sep 2011 | £315 | 30% |
| Aortic Aneurysm Global Clinical Trials Review Q2, 2011 |
May 2011 | £630 | 29% |
| Coagulation Disorders Market to 2017 Hemophilia A, The Largest Segment, to Witness a Decline in Growth Rate Due to Patent Expiries and Weak Pipeline |
Sep 2011 | £2,215 | 29% |
| Orphan Autoimmune Disorders to 2017 Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market |
Nov 2011 | £2,215 | 28% |
| Immunoglobulins Market to 2017 off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth |
Sep 2011 | £2,215 | 28% |
| Guillain Barre Syndrome (GBS) Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
May 2011 | £1,265 | 27% |
| Cystic Fibrosis - Pipeline Review H2 2011 |
Sep 2011 | £315 | 27% |
| Von Willebrand Disease - Pipeline Review H2 2011 |
Oct 2011 | £315 | 27% |
| Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics | Mar 2010 | £3,065 | 27% |
| New Developments in Treating Genetic Disorders: The Global Market | Mar 2010 | £3,065 | 26% |
| Hemophilia B - Pipeline Review H2 2011 |
Sep 2011 | £315 | 26% |
| Blood Banking and Blood Products Global Market Perspective |
Nov 2009 | £1,895 | 26% |
| Hemophilia A - Pipeline Review H2 2011 |
Sep 2011 | £315 | 25% |
| Von Willebrand Disease Global Clinical Trials Review H2, 2011 |
Nov 2011 | £630 | 25% |
| Top 100 Pharmaceutical Manufacturers Industry Analysis - Worldwide Business Performance Analysis |
Aug 2011 | £950 | 24% |
| Medicine (Pharmaceutical Drug): Analysis of French Companies | Aug 2011 | £495 | 21% |
| Blood Disorder Treatments | Jan 2007 | £2,760 | 21% |
| UK Pharmaceutical Manufacturers Business Performance Analysis |
Aug 2011 | £350 | 21% |
| Kawasaki Disease Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Dec 2011 | £2,215 | 21% |
| Biologic Therapeutic Drugs Technologies and Global Markets |
Jan 2011 | £3,065 | 20% |
